BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/6/2020 2:37:44 AM | Browse: 634 | Download: 977
 |
Received |
|
2019-12-15 06:19 |
|
Peer-Review Started |
|
2019-12-15 06:22 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2019-12-30 09:34 |
|
Revised |
|
2020-01-06 06:11 |
|
Second Decision |
|
2020-01-09 10:01 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-01-11 13:57 |
|
Articles in Press |
|
2020-01-11 13:57 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-01-13 13:25 |
|
Typeset the Manuscript |
|
2020-01-19 02:14 |
|
Publish the Manuscript Online |
|
2020-02-06 02:37 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Case Report |
| Article Title |
Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in gingiva: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qing Yu and Wen-Xia Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wen-Xia Wang, PhD, Doctor, Doctor, Department of Periodontology, School and Hospital of Stomatology, Shandong University, Shandong Key Laboratory of Oral Tissue Regeneration and Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, No. 44-1 Wenhua Road West, Jinan 250012, Shandong Province, China. wangwx@sdu.edu.cn |
| Key Words |
Camrelizumab; Adverse effects; Reactive capillary hemangioma; Gingiva; Case report; |
| Core Tip |
Camrelizumab (SHR-1210) is a kind of anti-PD-1 antibody. It was reported that a unique treatment-related adverse event was reactive capillary hemangioma. Notably, most reactive capillary hemangiomas occur on the skin, and this side effect is rarely seen in oral tissues. In this report, we describe a case of a patient who experienced gingival reactive capillary hemangioma during SHR-1210 treatment for lung cancer. |
| Publish Date |
2020-02-06 02:37 |
| Citation |
Yu Q, Wang WX. Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in gingiva: A case report. World J Clin Cases 2020; 8(3): 624-629 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i3/624.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i3.624 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
